Apellis: FDA OKs First and Only Treatment for Geographic Atrophy

 

• SYFOVRE slowed GA progression with increasing effects over time
  
  

• Approved for all patients with GA, with dosing flexibility every 25 to 60 days
  
  

• Well-demonstrated safety profile following ~12,000 injections over 24 months
  
  

• Conference call today at 4:30 p.m. ET

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide.

Conference Call and Webcast
Apellis will host a conference call and webcast to discuss the FDA’s approval of SYFOVRE today, Friday, February 17, 2023 at 4:30 p.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.

https://finance.yahoo.com/news/fda-approves-syfovre-pegcetacoplan-injection-210600759.html